Regional Account Manager- Neurology (Southern California - Not Los Ang…
Axsome Therapeutics Inc- Full Time
- Junior (1 to 2 years)
Cytokinetics is a late-stage, specialty cardiovascular biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which cardiac muscle performance is compromised. The company is developing small molecule drug candidates specifically engineered to impact myocardial muscle function and contractility. This territory also includes Daytona Beach, FL and Palm Coast, FL. Our passion is anchored in our four core values: - Patients are our North Star: Our actions and decisions are dedicated to benefiting patients and their caregivers. - Science is in our Soul: We are committed to scientific excellence, integrity, and critical thinking, free from external influences. - We > Me: Our strength lies in our unity and diversity. - Make it Happen: We navigate challenges with tenacity, resilience, and a forward-thinking mindset, always holding ourselves accountable for delivering impactful results.
As a Cardiovascular Account Specialist, you will introduce Cytokinetics in your dedicated territory and launch its first commercial product, a novel cardiac myosin inhibitor for Hypertrophic Cardiomyopathy (HCM). In this role, you will be responsible for driving performance by working synergistically with internal stakeholders and external customers. Success will require you to identify and develop business relationships with strategic IDNs and Hospitals, cardiology clinics, and specialty pharmacies while establishing yourself as a resource within these care settings. You will need to demonstrate strategic thinking, passion for our core values, and a proactive approach in supporting the Company’s Mission to help address patients’ unmet needs.
Develops drugs for muscle function disorders
Cytokinetics focuses on developing medicines that improve muscle function for patients with cardiovascular and neuromuscular diseases. Their products are small molecule drugs designed to either enhance or inhibit muscle function, tailored to specific therapeutic needs. The company has a pipeline of drugs, including omecamtiv mecarbil and reldesemtiv, which are in various stages of clinical trials. Unlike many competitors, Cytokinetics emphasizes rigorous scientific research and has conducted over 50 clinical trials to ensure the effectiveness of its treatments. The goal is to bring new therapies to market that address the unmet needs of patients suffering from conditions like heart failure, ALS, and HCM.